Literature DB >> 29571650

Early assessment of response to chemotherapy in lung cancer using dynamic contrast-enhanced MRI: a proof-of-concept study.

J Xu1, L Mei2, L Liu2, K Wang2, Z Zhou3, J Zheng4.   

Abstract

AIM: To evaluate the early treatment response to chemotherapy in patients with lung cancer using dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI).
MATERIALS AND METHODS: Twenty-two patients with lung cancer underwent DCE-MRI before chemotherapy and 1 week after the start of the first course of chemotherapy. Pharmacokinetic parameters (Ktrans, Kep, and Ve) derived from DCE MRI were generated using the post-processing platform. These parameters and corresponding changes were compared between responders and non-responders after treatment using Student's t or Mann-Whitney U-tests. Diagnostic efficiency of kinetic parameters in differentiating responders from non-responders after 1 week of chemotherapy was also investigated.
RESULTS: Thirteen responders after 1 week of chemotherapy had a significant decrease in Ktrans and Ve compared with the pretreatment value (p<0.05), and had no significant changes in Kep (p>0.05). Nine non-responders had no significant changes in Ktrans, Kep, and Ve compared with the pretreatment value (p>0.05). Changes in Ktrans (ΔKtrans) were significantly larger in responders than that in non-responders (p<0.05). Changes in Ve and Kep (ΔVe andΔKep) were without statistical significance after treatment between responders and non-responders (p>0.05). The cut-off value of ΔKtrans in best predicting tumour's chemotherapeutic response was 0.032/min and the corresponding AUC (area under the curve), sensitivity, specificity, and accuracy were 0.821, 84.62%, 77.78%, and 81.82%, respectively.
CONCLUSION: DCE MRI may be useful for evaluating the early response to chemotherapy in patients with lung cancer, but larger, more definitive studies are needed.
Copyright © 2018 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29571650     DOI: 10.1016/j.crad.2018.02.013

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  4 in total

1.  Novel Thoracic MRI Approaches for the Assessment of Pulmonary Physiology and Inflammation.

Authors:  Jonathan P Brooke; Ian P Hall
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Correlation between quantitative perfusion histogram parameters of DCE-MRI and PTEN, P-Akt and m-TOR in different pathological types of lung cancer.

Authors:  Bingqian Zhang; Zhenhua Zhao; Ya'nan Huang; Haijia Mao; Mingyue Zou; Cheng Wang; Guangmao Yu; Minming Zhang
Journal:  BMC Med Imaging       Date:  2021-04-17       Impact factor: 1.930

3.  Reproducibility of dynamic contrast enhanced MRI derived transfer coefficient Ktrans in lung cancer.

Authors:  Jean-Philip Daniel Weber; Judith Eva Spiro; Matthias Scheffler; Jürgen Wolf; Lucia Nogova; Marc Tittgemeyer; David Maintz; Hendrik Laue; Thorsten Persigehl
Journal:  PLoS One       Date:  2022-03-08       Impact factor: 3.240

4.  Assessment of Early Response to Lung Cancer Chemotherapy by Semiquantitative Analysis of Dynamic Contrast-Enhanced MRI.

Authors:  Jiang Zhu; Jian Yun; Kaixiang Wang; Liangqing Liu; Jiangang Zheng; Li Mei; Jianxing Xu
Journal:  Dis Markers       Date:  2022-07-23       Impact factor: 3.464

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.